Wolverine Asset Management LLC Sells 20,815 Shares of Amedisys, Inc. (NASDAQ:AMED)

Wolverine Asset Management LLC decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 59.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,966 shares of the health services provider’s stock after selling 20,815 shares during the quarter. Wolverine Asset Management LLC’s holdings in Amedisys were worth $1,268,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. grew its position in shares of Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after buying an additional 124 shares in the last quarter. HBW Advisory Services LLC purchased a new stake in shares of Amedisys during the 4th quarter worth $38,000. Versant Capital Management Inc lifted its stake in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares during the last quarter. KBC Group NV purchased a new stake in shares of Amedisys during the 3rd quarter worth $63,000. Finally, Venturi Wealth Management LLC lifted its stake in shares of Amedisys by 397.4% during the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after purchasing an additional 779 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Trading Down 0.7 %

Amedisys stock opened at $90.43 on Friday. The stock has a 50-day moving average of $90.74 and a two-hundred day moving average of $93.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a one year low of $82.15 and a one year high of $98.95. The stock has a market cap of $2.96 billion, a PE ratio of 35.88, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research note on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Amedisys has an average rating of “Hold” and an average target price of $100.75.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.